Mizuho raised the firm’s price target on Tandem Diabetes (TNDM) to $18 from $16 and keeps a Neutral rating on the shares.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- Tandem Diabetes Care: Strong Buy Rating Backed by Strategic Growth Initiatives and Attractive Valuation
- Tandem Diabetes price target raised to $55 from $51 at Barclays
- Tandem Diabetes price target raised to $18 from $16 at Baird
- Tandem Diabetes Care Reports Record Third-Quarter Sales
- Tandem Diabetes Care: Strong Q3 Performance and Positive Outlook Justify Buy Rating